VIATRIS INC. Proceeds from Long-Term Debt Issued
VIATRIS INC. (VTRS) reported Proceeds from Long-Term Debt Issued of $1.30 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-08-06
- VIATRIS INC. proceeds from issuance of long-term debt for the quarter ending 2023-12-31 was $300.00K, a 200.00% increase year-over-year.
- VIATRIS INC. proceeds from issuance of long-term debt for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. proceeds from issuance of long-term debt for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. proceeds from issuance of long-term debt for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. proceeds from issuance of long-term debt for fiscal 2025 was $0.00.
- VIATRIS INC. proceeds from issuance of long-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- VIATRIS INC. proceeds from issuance of long-term debt for fiscal 2023 was $300.00K, a 99.98% decline from fiscal 2022.
- VIATRIS INC. proceeds from issuance of long-term debt for fiscal 2022 was $1.88B, a 9.68% increase from fiscal 2021.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 4 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 7 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.30B 10-Q · filed 2026-08-06 | |||||
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | |||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||||
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $300.00K derived: sum of 2 quarters · filed 2026-02-26 | $300.00K derived: sum of 3 quarters · filed 2026-02-26 | $300.00K 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | $100.00K derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $100.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.08B derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | $100.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.08B derived: sum of 3 quarters · filed 2025-02-27 | $1.88B derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.08B derived: sum of 2 quarters · filed 2025-02-27 | $1.88B derived: sum of 3 quarters · filed 2025-02-27 | $1.88B 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $1.08B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.88B derived: sum of 2 quarters · filed 2023-11-08 | $1.88B 10-Q · filed 2023-11-08 | $1.88B derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | $795.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $795.40M 10-Q · filed 2023-08-07 | $795.40M derived: sum of 3 quarters · filed 2024-02-28 | $1.61B derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-08 | $100.00K derived: sum of 2 quarters · filed 2024-02-28 | $810.10M derived: sum of 3 quarters · filed 2024-02-28 | $1.71B derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $810.00M derived: sum of 2 quarters · filed 2024-02-28 | $1.71B derived: sum of 3 quarters · filed 2024-02-28 | $1.71B 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $810.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.71B derived: sum of 2 quarters · filed 2022-11-07 | $1.71B 10-Q · filed 2022-11-07 | $2.66B derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-06-30 | $900.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $900.10M 10-Q · filed 2022-08-08 | $1.85B derived: sum of 3 quarters · filed 2023-02-27 | $1.85B derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | $950.10M derived: sum of 2 quarters · filed 2023-02-27 | $950.10M derived: sum of 3 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $950.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $950.10M derived: sum of 2 quarters · filed 2023-02-27 | $983.30M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $33.20M 10-Q · filed 2021-11-08 | ||||
| 2020-09-27 | $11.44B derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $11.44B derived: sum of 2 quarters · filed 2021-08-09 | $11.48B 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $33.20M 10-Q · filed 2021-08-09 | ||||
| 2020-06-28 | $11.40B 10-Q · filed 2020-11-10 | $11.48B 10-Q · filed 2020-08-12 | ||||
| 2020-03-31 | $33.10M 10-Q · filed 2021-05-10 | |||||
| 2019-12-31 | $7.40M 10-K · filed 2022-02-28 | |||||
| 2019-09-29 | $0.00 10-Q · filed 2020-11-10 | |||||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | |||||
| 2018-12-31 | $2.58B 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |